MRVI (Maravai LifeSciences Holdings) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRVI Maravai LifeSciences Holdings Inc MRVI
62 GF Score
Price $6.74
GF Value $3.82
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Maravai LifeSciences Holdings Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

MRVI
62GF Score
Maravai LifeSciences Holdings Inc MRVI
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?

Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued. The current stock price of $6.74 is trading 76.3% above its estimated GF Value™ of $3.82. GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.

Key valuation signals for MRVI:

  • Dividends Received:
  • GF Value™: $3.82 vs. price of $6.74 (76.3% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maravai LifeSciences Holdings Business Description

Other Exchanges MAR:Germany
Address 10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score

Get the complete analysis for MRVI

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.74
Price
$3.82
GF Value